Healthcare Sales & Marketing Network News: emapalumab

Searching News Database: emapalumab

HSMN NewsFeed - 25 Feb 2022
Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Jun 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2019
Sobi Acquires Emapalumab and Related Assets
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Biopharmaceuticals Acquisitions

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.